Sen. Hatch, Rep. Waxman Put Pharma Industry On Notice About Likely Congressional Action for 'Authorized' Generics.

CHEVY CHASE, Md. & ARLINGTON, Va. -- FDC Reports, Inc., publisher of "The Pink Sheet," in partnership with Polidais LLC, today announces breaking news from the Drug & Device Dialogue interactive audio conference series.

Sen. Orrin Hatch (R-Utah) and Rep. Henry Waxman (D-Calif.) delivered a warning shot across the bow for pharmaceutical companies who have entered into "authorized" generic agreements during the Oct. 6 session of a two-day Drug & Device Dialogue conference. "I think that's certainly an area that not just (Rep. Waxman) and I but everybody in Congress is going to have to explore," Sen. Hatch remarked.

Among several pointed observations about the impact of authorized generics on competition in the pharmaceutical sector, Rep. Waxman maintained that brand companies are "circumventing the intent" of the 1984 Hatch-Waxman Act. William Schultz, Partner at Zuckerman Spaeder, and Carl Seiden, Senior Analyst-Pharmaceuticals, UBS Investment Research, also provided keen insight during the Oct. 6 session into many crucial challenges facing brand drug, generic and biotech firms.

"Considering that Hatch-Waxman is absolutely critical to the pharmaceutical industry's core business model and that changes to the Act will have profound ramifications industry-wide, stakeholders cannot afford to miss these valuable insights from Sen. Hatch, Rep. Waxman and our other prominent speakers," says Karl Uhlendorf, Executive Editor with Drug & Device Dialogue. "Our impressive line-up on day two promises to be similarly indispensable."

It's not too late to register for the live Oct. 7 event or archived access to the session featuring Sen. Hatch and Rep. Waxman. For complete pricing information or to register, visit www.drugdevicedialogue.com or call 1-800-332-2181.

The Oct. 7 session of the Drug & Device Dialogue event will further explore possible legislative and/or regulatory actions on both "authorized" generics and follow-on biologics as a dynamic panel of speakers tackle these complicated issues. Building on the comments by Sen. Hatch and Rep. Waxman will be Fred Killion, General Counsel, Barr Laboratories, Jeffrey Chasnow, Senior Corporate Counsel, Pfizer, David Balto, Partner, Robins, Kaplan, Miller & Ciresi, Kenneth Seamon, PhD, VP-Regulatory Affairs, Amgen, and Kay Holcombe, Executive VP, Policy Directions.

Sign up now by visiting www.drugdevicedialogue.com or calling 800-332-2181.

Drug & Device Dialogue online symposiums feature high-quality audio presentations over the Internet or telephone, complemented by synchronized slide presentations, background materials and user-friendly Q&A.

FDC Reports is a division of the Elsevier Company. Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, the company publishes more than 1,800 journals and 2,200 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect (www.sciencedirect.com) and MD Consult (www.mdconsult) bibliographic databases, online reference works and subject specific portals.